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Objective. To describe and evaluate the outcomes of a support programme for patients with virological failure while receiving 
second-line antiretroviral therapy (ART) in South Africa.
Method. We described a comprehensive medical and counselling patient support programme for patients receiving second-
line ART and with two consecutive viral loads (VLs) >1 000 copies/ml. Patients with >3 months follow-up and at least one VL 
measurement after inclusion in the programme were eligible for analysis.
Results. Of 69 patients enrolled in the programme, 40 had at least one follow-up VL and no known drug resistance at enrolment; 
27 (68%) of these re-suppressed while remaining on second-line ART following enhanced adherence support. The majority 
(18/27; 67%) achieved re-suppression within the first 3 months in the programme. Five patients with diagnosed second-line 
drug resistance achieved viral re-suppression (<400 copies/ml) after being switched to third-line ART. Seven patients (7/40; 
18%) did not achieve viral re-suppression after 9 months in the programme: 6 with known adherence problems (4 without drug 
resistance on genotype) and 1 with a VL <1 000 copies/ml. Overall, 3 patients (4%) died, 3 (4%) were lost to follow-up and 2 
(3%) were transferred out.
Conclusion. Our experience from a routine programme demonstrates that with targeted adherence support, the majority of 
patients who were viraemic while receiving second-line ART returned to an undetectable VL within 3 months. By increasing the 
time receiving second-line ART and decreasing the need for genotypes and/or third-line ART, this intervention may reduce costs. 
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At the end of 2012, 35 million people were 
estimated to be living with HIV worldwide – 
most in sub-Saharan Africa. [1] Antiretroviral 
therapy (ART) was first intro duced in South 
Africa (SA) through pilot projects in 2001. In 
2004, the country launched its public sector ART programme, 
now the largest ART programme in the world. By mid-2013, 
approximately 2.5 million people had initiated ART free of 
charge through the public sector.[2] 
As increasing numbers of patients are enrolled in treat-
ment regimens, there is an increase in the number failing 
first-line ART and being switched to second-line ART.[3-6] The 
durability of second-line regimens is not well-established and 
there is growing concern in SA and elsewhere regarding the 
management of second-line failure, given the high cost of 
third-line ART and limited treatment options. In one study 
conducted in Soweto, SA, about one-third of patients receiving 
the second-line lopinavir/ritonavir (LPV/r)-based regimen 
were found to be viraemic.[7] In another study in Khayelitsha, 
SA, patients receiving second-line ART were less likely to be 
virologically suppressed than patients remaining on first-line 
ART at equivalent durations of treatment (odds ratio (OR) 
0.51; 95% confidence interval (CI) 0.26 - 1.01).[8]
North American and European ART guidelines recommend 
that genotyping governs decisions on the appropriate treatment 
for patients failing second-line ART.[9] In Khayelitsha, where 
routine viral load (VL) testing is available, targeted genotyping 
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in 2011 on the basis of expert advice. The 
most recent SA ART guidelines, published in 
2013, recommend that specialist systems be 
created within programmes to guide clinical 
management and access to third-line regimens 
based on genotype resistance testing and 
expert opinion.[10]
Previous studies have found that only a 
minority of second-line patients with virolo-
g ical failure in the Khayelitsha programme 
had major protease inhibitor (PI) mutations 
necessitating third-line ART.[11] This suggests 
that the high VL measurements observed may 
largely be explained by adherence difficulties. 
In this study, we describe an enhanced patient 
support programme and short-term outcomes 
for patients with sustained viraemia on 




Khayelitsha sub-district (population ~500 000 
inhabitants) is located on the outskirts of 
Cape Town, SA, and has one of the highest 
burdens of HIV and tuberculosis (TB) in the 
country. In 2010, antenatal HIV prevalence 
was measured at 26%; the TB case-notification 
rate reached nearly 1 500/100 000 inhabitants, 
and the TB/ HIV co-infection rate was close to 
73%.[12]
The Khayelitsha programme was the first 
in SA to provide ART at the primary care 
level in the public sector. The programme 
was established in 2001 by Médecins 
Sans Frontières (MSF) and the Provincial 
Government of the Western Cape (PGWC) 
and has been described previously.[8,12,19] MSF’s 
role evolved from the provision of first-line 
ART to piloting models of primary care for 
drug-resistant tuberculosis (DR-TB), long-
term ART and vulnerable groups such as 
children, youth, pregnant women and men. By 
the end of 2011, over 20 000 patients remained 
in ART care provided by the Department of 
Health in Khayelitsha.[12]
Ubuntu Clinic, the study site with the largest 
and oldest cohort of patients receiving ART in 
Khayelitsha, had initiated over 6 000 patients 
on ART, of whom 482 (7%) were receiving 
second-line PI-based regimens (mainly LPV/
r-based) at the time of the study. 
The PGWC ART guidelines recommend 
a first VL measurement four months after 
ART initiation. Follow-up VL monitoring 
is recommended 12 months after treatment 
initiation and annually thereafter. Patients 
with a VL ≥1 000 copies/ml and no medical 
reasons for a virological breakthrough receive 
adherence counselling and a follow-up VL 
measurement three months later. Virological 
treatment failure is defined as having two 
consecutive VLs ≥1 000 copies/ml. Such 
patients are switched to an appropriate 
second-line LPV/r-based regimen. 
Second-line support clinic
Prior to the introduction of the intervention, 
and as is common in this setting, patients 
with a detectable VL routinely received at 
least one adherence session performed by 
clinic counsellors. These sessions focused on 
re-educating patients on treatment literacy 
rather than problem-solving around specific 
adherence barriers. Clinicians and counsellors 
often found it challenging and frustrating to 
deal with patients who were failing treatment 
and had no further treatment options. 
In 2010, MSF partnered with the PGWC to 
pilot a ‘second-line failure clinic’ intervention 
at Ubuntu clinic, targeting patients receiving 
second-line ART and with two or more 
consecutive VL measurements ≥1 000 copies/ml.
All patients enrolled in the programme 
were offered a comprehensive package of 
medi cal and counselling support (Fig. 1), and 
were followed up by clinical staff (doctor and/
or nurse). Counsellors conducted a simple 
screen for substance abuse and depression 
at the enrolment visit and referred patients 
for additional services accordingly. A typical 
visit would consist of a medical visit, an 
individual adherence support session and a 
group support activity.
Medical visits carried out by a clinician 
(medical officer or professional nurse) 
focused on clinical issues relating to treatment 
failure, such as opportunistic infections, drug 
interactions, side-effects and possible drug 
resistance. The clinician also engaged in 
adherence support and HIV drug resistance 
tests were only performed when patients failed 
to obtain virological re-suppression after all 
adherence barriers were addressed. Individual 
adherence support sessions were conducted by 
counsellors. During these individual sessions, 
the patient’s specific adherence barriers were 
identified and assistance was provided to 
problem-solve these issues. During monthly 
follow-up visits, patients were encouraged 
to report back on the progress that they had 
made or the difficulties that they still faced in 
adhering to treatment. Adherence barriers and 
plans made were noted in the patient’s folder 
to aid follow-up. 
In addition, patients were invited to 
attend support group sessions facilitated by 
a counsellor. Grouping patients with similar 
difficulties encouraged patients to share their 
barriers and solutions, and also promoted 
openness and honesty. 
After a period of three months in the 
second-line failure intervention, a VL 
measurement was repeated. Patients who 
achieved virological suppression were then 
referred back to routine clinic care. Patients 
who did not achieve virological suppression 
were retained in the intervention and assessed 
for HIV drug resistance testing.
This intervention ensured that the small 
number of patients who were struggling on 
second-line ART were identified, temporarily 
removed from the normal flow of the clinic, 
and given enhanced attention and support, 
which is challenging to offer to all patients in 
a busy ART clinic.
Outcome evaluation
The primary outcome was virological re-
suppression, defined as achieving a VL ≤400 
copies/ml after having two consecutive VL 
measurements ≥1 000 copies/ml. Patients who 
had no contact with the clinic for 6 months were 
regarded as lost to follow-up (LTFU). Those 
patients who requested transfer to another 
health facility were considered transferred out 
(TO). Data for each patient on the date of first-
line ART initiation, initiation of second-line 
therapy, VL measurements and the dates of VL 
tests were extracted from routinely collected 
data in the electronic patient register in the 
clinic. Date of registration in the clinic was 
Second-line ART
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captured from the paper register used by the 
doctors to track patients in care. Information 
regarding barriers to adherence was extracted 
from counselling notes.
Statistical analysis
Enrolled patients with less than three 
months of follow-up and patients who did 
not have a follow-up VL measurement in 
the programme were excluded from the 
analysis. We described the treatment and VL 
history of patients during the study period 
with frequencies for categorical variables and 
medians and interquartile ranges (IQRs) for 
continuous variables. The following variables 
were included: duration of first-line ART, type 
of first-line ART, duration (years) receiving 
first-line ART before the first and second 
of two consecutive VLs >1 000 copies/ml, 
duration and choice of second-line treatment, 
and duration in the second-line failure 
programme. The analysis of routine cohort 
data was approved by the University of Cape 
Town’s Research Ethics Committee. 
Results
From January to December 2011, a total of 
69 patients were enrolled in the programme 
(Fig. 2); 29 were excluded from the analysis 
as they had not had a follow-up VL. Four 
patients who had known drug resistance at 
the time of enrolment were also excluded from 
the analysis. The median duration on first-
line treatment was 3.4 years (IQR 2.1 - 4.3). 
The median duration of the first-line regimen 
before two consecutive elevated VLs was 
1.7 years (IQR 0.9 - 2.5). Once switched to a 
second-line regimen, the median time to the 
first detectable VL measurement was 0.7 years 
(IQR 0.4 - 1.1).
Overall, during 9 months of follow-up, 27 
of the remaining 40 patients (68%) achieved 
virological suppression while remaining 
on second-line treatment. One patient was 
switched to third-line ART after genotyping 
showed PI resistance. Seven patients (18%) 
continued to experience viraemia, either 
with known adherence problems or having 
been genotyped and found to be treatment-
sensitive; none of these patients was switched 
to third-line ART and all continued in the 
programme. Five patients left the programme 
due to death, LTFU or TO.
Timing of virological 
re-suppression
Eighteen out of 40 patients (46%) achieved 
virological re-suppression within 3 months, 7 
(18%) within 6 months, and 2 (5%) within 9 
months. One patient underwent genotyping, 
was found to have PI resistance and was 
switched to third-line ART, subsequently re-
suppressing within 3 months. 
After re-suppression, 19% (5/27) of patients 
ex peri en ced a recurrence of viraemia: 3 of the 
18 who suppressed at three months, and two 
of the seven patients who suppressed at six 
months. Of the seven patients who failed to 
re-suppress, four were genotyped and found 
to have a drug-sensitive virus; two had known 
adherence issues (one due to alcoholism, one 
for unspecified reasons) and one had a VL of 
400 - 1 000 copies/ml, and could therefore not 
be genotyped.
Obstacles to adherence
The four main obstacles to adherence reported 
by patients entering the programme were: 
issues regarding the dosing schedule and not 
having a fixed routine; ignorance about the 
need for good adherence; a previous negative 
experience with clinic staff; and simply 
forgetting to take the drugs as needed. The 
action plans to address these barriers were: 
changing the dosing schedule; treatment 
education through support groups; specific 
clinic staff dedicated to patients with treatment 
failure; and reinforced counselling support. 
Discussion
In this routine programme, more than two-
thirds of patients failing second-line ART 
achieved virological re-suppression without 
changing regimen and following an enhanced 
patient-support intervention. The majority of 
patients re-suppressed within three months 
after enrolment in the programme. 
Our findings are important for a number 
of reasons. Firstly, patients failing second-
line ART have limited treatment options 
available as third-line regimens are extremely 
costly. In our study population, the median 
duration of the first-line regimen before two 
consecutive elevated VLs was 1.7 years and 
the median time to the first detectable VL 
measurement after being switched to a second-
line regimen was 0.7 years. This suggests 
that these may be patients with significant 
barriers to adherence. Remaining on a failing 
ART regimen without acting on the reasons 
for treatment failure could compromise the 
efficacy of future treatment options. Failure 
rates of second-line therapy are higher than 
reported rates of failure of first-line therapy. [13] 
A systematic review and meta-analysis of 
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Fig. 2. Flow diagram of outcomes of patients failing second-line antiretroviral therapy enrolled in a 
comprehensive medical and counselling patient support programme at a primary healthcare clinic, in 
Khayelitsha, South Africa in 2011. (TO = transfer out; LTFU = loss to follow-up; VL1, VL2, VL3 = first, second 
and third VL measurements after enrolment into the programme.)
* 3 patients experienced a VL >400 copies/ml at VL2.
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second-line ART in resource-limited settings found a high proportion 
with virological failure, with most failures occurring within six months 
after initiation of second-line therapy.[14] For long-term health to be 
maintained in resource-limited settings where treatment options are 
limited, it is important to maximise the clinical benefits derived from 
each regimen. This has implications for the wide-scale rollout of ART in 
SA as well as in other resource-limited settings. The enhanced patient-
support programme requires additional resources for a small number 
of specific patients, but may avoid unnecessary and costly regimen 
switching. The outcomes of this pilot programme are now informing 
the implementation of an adherence-support programme for patients 
at risk of failing first-line therapy.[15]
Adherence to ART is a key factor for achieving successful treatment 
outcomes in individual patients and for the success of large-scale ART 
programmes.[16] To maintain virological suppression, evidence suggests 
that individuals are required to take at least 80% of their medication 
for PI-based therapies,[17-19] and at least 95% of non-nucleoside-based 
therapies.[16] An emerging challenge for large ART programmes is 
maintaining patient-centred care while enrolment is on-going and 
total patient numbers are constantly increasing.[20] Our findings suggest 
that providing continuity of care for a period of time under the same 
healthcare staff may promote adherence. 
Access to genotyping and third-line regimens remains a major 
challenge for public sector programmes. As has been reported by a 
previous study from the same and other programmes,[21,22] most of the 
samples genotyped remained susceptible to PIs due to a lack of drug 
exposure, with adherence problems constituting the major issue. In 
another study conducted in Khayelitsha,[11] only two of 37 genotyped 
samples had major PI mutations. Nevertheless, some second-line 
virological failures do have major PI mutations that confer resistance 
and third-line ART will likely become a growing concern. The model 
of care described here provides an approach to limit the need for costly 
genotyping by identifying those patients who are non-adherent. In our 
cohort, only five out of 40 possible samples were genotyped, and 20% 
of those were found to be resistant. In this way, such a model may be 
cost-saving. 
Five patients experienced virological rebound after VL re-suppression 
and 18% of all patients did not achieve re-suppression while remaining 
in the programme. These patients chose to remain in the programme 
as they experienced continued value in the adherence support received. 
Adherence problems and/or treatment barriers were identified, 
highlighting the need for further research on optimal adherence support. 
Conclusion
Our findings from an operational setting within routine care are 
promising, as they demonstrate that patients failing second-line 
treatment can become adherent with programmatic support. Our 
study resulted in increased durability of the second-line ART regimen, 
decreasing the need for costly third-line regimens and preventing many 
unnecessary genotypes by early identification of, and action on barriers 
to adherence. While our descriptive study shows satisfactory short-term 
outcomes, the long-term impact is as yet uncertain and remains to be 
evaluated.
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